This Week in Psychedelics

Wanna get ahead in corporate America? Consider LSD! And Alabama is famous for football, but could it soon be famous for psychedelics too?

October 22, 2023

This Week...

Diamond Therapeutics announced the enrollment of the first patient in an FDA-approved clinical trial conducted at the University of Alabama at Birmingham.  

The UAB-Diamond Trial will enroll 60 patients to evaluate the treatment of low doses of psilocybin in demoralization, a condition that involves feelings of hopelessness and meaninglessness. The trial will assess initial signals of efficacy, feasibility, and potential mechanisms of action. Psilocybin will be administered across a series of low doses that are not expected to produce hallucinogenic or other subjective effects, which may limit broad use. Here’s more:

The City Council in Eureka, California, adopted a resolution to decriminalize psychedelic plants and fungi, making enforcement of laws against personal use, cultivation, and possession a low priority for police. It’s at least the fifth local jurisdiction in the state to embrace the policy change.

The resolution, which passed unanimously on Tuesday, deprioritized the investigation and arrest of adults 21 and older for certain psychedelics-related activity. Check it out:

A new study was published in the journal Substance Use & Misuse, which investigated LSD use among business managers.

The findings indicate that temporal trends in past year LSD use depend on employees’ hierarchical rank in their organization. They suggest that business managers, regardless of gender, are becoming increasingly interested in the potential competitive advantages that LSD may offer. Here’s more:

Did You Know?

Did you know there’s a psychedelic library in midtown Manhattan?

It’s called Athenaeum, and was recently featured in the New York Times.

By day, it’s a quiet reading room and co-working space, where members and day-pass holders can work or chat over a cup of coffee. After hours, it turns into an event venue, hosting everything from art openings to lectures to drug-themed comedy shows. You can check out the New York Times piece here: